Last updated: July 27, 2026
- Case: Eli Lilly and Co. v. Teva Pharmaceuticals USA, Inc., 1:16-cv-00596 (D. N.J.).
- Parties: Eli Lilly and Company (and related Lilly entities) vs. Teva Pharmaceuticals USA, Inc.
- Core business issue: Lilly alleged Teva’s proposed generic infringed Lilly patents listed for the relevant Lilly product in the FDA Orange Book and sought injunctive relief and damages.
- Outcome: Not provided in the input. Without the docket disposition and the asserted patent list, a complete litigation summary (claims, patent numbers, procedural posture, and final result) cannot be produced.
H1: Eli Lilly vs. Teva Pharmaceuticals USA (1:16-cv-00596) litigation summary, patents asserted, and outcome analysis
What patents were asserted in Eli Lilly and Company v. Teva (1:16-cv-00596)?
A litigation summary requires the asserted Orange Book patents (USPTO/Orange Book numbers, claims, and title/priority details). Those details are not present in the provided material, so the asserted-patent set and infringement theories cannot be stated accurately.
Which Lilly product and Orange Book listing drove the case?
The specific Lilly drug at issue determines:
- the Orange Book patent family (drug substance, drug product, formulation, or method-of-use)
- the relevant FDA ANDA paragraph IV posture
- the claim construction issues that typically dominate Hatch-Waxman cases
The product identity is not provided.
What infringement claims did Lilly plead against Teva in 1:16-cv-00596?
A credible claim-level analysis depends on:
- the independent and dependent claims asserted
- whether Lilly pursued direct infringement, induced infringement, or contributory infringement
- whether the complaint targeted ANDA label/carve-outs or manufacturing process
No complaint claims or infringement counts were supplied.
What defenses did Teva raise in Eli Lilly v. Teva (1:16-cv-00596)?
Hatch-Waxman defendants commonly raise:
- invalidity (anticipation, obviousness, lack of written description/enablement)
- non-infringement based on Teva’s proposed labeling or formulation
- prosecution history estoppel or claim construction limits
Those defenses and their procedural timing are not present.
What happened procedurally in 1:16-cv-00596 (motions, hearings, claim construction, trial)?
A litigation timeline requires docket events such as:
- preliminary injunction motion (if any) and related briefing
- Markman/claim construction scheduling
- dispositive motion rulings
- settlement vs. judgment and any appeal
The case procedural disposition is not provided.
How did the court rule in 1:16-cv-00596 and what is the final outcome?
A full outcome analysis requires the final order(s), including:
- whether the case ended via final judgment, consent judgment, or dismissal
- whether any patents were held infringed/invalid
- whether there was a Section 271(e)(2)/(e)(4) determination tied to the ANDA
No final disposition is included.
Did Teva launch “at risk” and what did Lilly obtain (injunction, settlement, or damages)?
Business impact hinges on:
- whether Teva was enjoined from FDA approval or launch
- whether a settlement agreement delayed launch (and by how long)
- whether damages were awarded or waived
No launch timing, settlement terms, or damages info is supplied.
What is the Orange Book status of the Lilly patents tied to 1:16-cv-00596?
To map this litigation to exclusivity and generic risk, an analysis needs:
- Orange Book patent list
- expiration dates and any pediatric exclusivity adjustments
- whether patents were listed for drug substance vs drug product vs method of use
- whether Teva’s ANDA included paragraph IV certifications
None of this is provided.
When do the asserted patents expire and when does Eli Lilly lose exclusivity?
Patent expiration and exclusivity timing requires the asserted patent numbers and their expiration/pediatric windows. Without those, any timeline would be speculative.
How strong is the patent estate for the Lilly product implicated in 1:16-cv-00596?
A strength assessment typically aggregates:
- remaining life of core patents
- claim breadth indicators (composition vs. formulation vs. method-of-use)
- past enforcement outcomes (other cases involving the same family)
The patent estate details are not provided.
What Paragraph IV arguments did Lilly use and how did the court treat validity vs infringement?
A paragraph IV-centric analysis depends on:
- Lilly’s paragraph IV narrative and which certifications were challenged
- the court’s rulings on invalidity and/or non-infringement
No paragraph IV briefing content is provided.
Which companies are challenging the same Lilly patent family (biosimilar or generic landscape)?
To build a competitive risk map:
- identify other filers against the same Orange Book-listed patents
- list other ANDAs with paragraph IV certifications and their dates
No Orange Book family or broader competitor activity is included.
How does Teva’s proposed product compare with Lilly’s patented product (formulation, dosage form, label)?
A technical infringement map needs:
- proposed dosage form and strength(s)
- excipients or formulation elements claimed as novel
- differences between Lilly’s commercial product and Teva’s proposed ANDA labeling
No formulation or label details are provided.
What manufacturing/IP barriers could affect Teva’s path after 1:16-cv-00596?
This requires knowing:
- whether the patents asserted include manufacturing-process limitations
- whether there were design-around allowances during settlement
No such details are present.
Key Takeaways
- A complete, decision-grade litigation summary of Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc., 1:16-cv-00596 cannot be produced from the provided input because the material facts needed for accuracy are missing: the asserted patent list, claims, procedural history, and final disposition.
- For business use, the critical artifacts to translate this docket into risk and timelines are the complaint’s asserted patents and the docket’s final orders or settlement terms. Those are not present in the request.
FAQs
- What patents are typically asserted in Eli Lilly Hatch-Waxman cases like 1:16-cv-00596?
- How does a district court’s claim construction ruling change infringement risk in paragraph IV cases?
- What settlement structures most commonly delay generic launch in FDA ANDA litigation?
- How do pediatric exclusivity and patent term adjustments affect generic entry timing when an Orange Book list is litigated?
- What post-judgment pathways (appeal, re-certification, stipulated dismissals) change the enforceability window?
References
- Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc., 1:16-cv-00596 (D. N.J.) (no docket documents provided in input).
